BACKGROUND: Phase I and phase II HIV-1 vaccine trials have revealed increases in risky sexual activity among study subjects during the trials, perhaps because the subjects believe that the vaccine being tested is efficacious; subjects may thus suffer harm from their participation. We evaluated the sexual behaviour of Canadian men who have sex with men (MSM) who participated in the phase III Vax004 trial of anHIV-1 vaccine. METHODS: Using self-reports of sexual behaviours during the 6 months before trial entry as a baseline, we determined changes in reported sexual behaviour after 6, 12 and 18 months of participation in the trial. RESULTS:Of 291 HIV-seronegative MSM enrolled from July to October 1999, 260 (89%) completed 18 months of follow-up, 19 (7%) experienced seroconversion, and 12 (4%) did not complete follow-up. Unprotected receptive anal intercourse during the previous 6 months with partners whose HIV-1 serostatus was positive or unknown was reported by 21% of men at enrollment and by 27% at any point during 18 months of follow-up. No increase in this behaviour from baseline was reported by participants, including among men who were motivated to enroll because of expected protection from HIV-1 infection, men who believed they had received the vaccine, men who believed that the vaccine had greater than 50% efficacy, or men who believed that they had received the vaccine and that vaccine efficacy was greater than 50%. INTERPRETATION:MSM can be successfully enrolled in HIV-1 vaccine efficacy trials without evident increases in those sexual behaviours most associated with HIV-1 risk.
RCT Entities:
BACKGROUND: Phase I and phase II HIV-1 vaccine trials have revealed increases in risky sexual activity among study subjects during the trials, perhaps because the subjects believe that the vaccine being tested is efficacious; subjects may thus suffer harm from their participation. We evaluated the sexual behaviour of Canadian men who have sex with men (MSM) who participated in the phase III Vax004 trial of an HIV-1 vaccine. METHODS: Using self-reports of sexual behaviours during the 6 months before trial entry as a baseline, we determined changes in reported sexual behaviour after 6, 12 and 18 months of participation in the trial. RESULTS: Of 291 HIV-seronegative MSM enrolled from July to October 1999, 260 (89%) completed 18 months of follow-up, 19 (7%) experienced seroconversion, and 12 (4%) did not complete follow-up. Unprotected receptive anal intercourse during the previous 6 months with partners whose HIV-1 serostatus was positive or unknown was reported by 21% of men at enrollment and by 27% at any point during 18 months of follow-up. No increase in this behaviour from baseline was reported by participants, including among men who were motivated to enroll because of expected protection from HIV-1 infection, men who believed they had received the vaccine, men who believed that the vaccine had greater than 50% efficacy, or men who believed that they had received the vaccine and that vaccine efficacy was greater than 50%. INTERPRETATION: MSM can be successfully enrolled in HIV-1 vaccine efficacy trials without evident increases in those sexual behaviours most associated with HIV-1 risk.
Authors: Donald P Francis; William L Heyward; Vladimir Popovic; Patti Orozco-Cronin; Karin Orelind; Carolyn Gee; Adrian Hirsch; Tina Ippolito; Aimee Luck; Michael Longhi; Vineeta Gulati; Nathan Winslow; Marc Gurwith; Faruk Sinangil; Phillip W Berman Journal: AIDS Date: 2003-01-24 Impact factor: 4.177
Authors: M A Piaseczna; K J Craib; K Li; K Chan; A E Weber; S A Strathdee; S Martindale; M T Schechter; R S Hogg Journal: J Acquir Immune Defic Syndr Date: 2001-10-01 Impact factor: 3.731
Authors: Liviana Calzavara; Ann N Burchell; Carol Major; Robert S Remis; Paul Corey; Ted Myers; Peggy Millson; Evelyn Wallace Journal: AIDS Date: 2002-08-16 Impact factor: 4.177
Authors: Patrick G Yeni; Scott M Hammer; Charles C J Carpenter; David A Cooper; Margaret A Fischl; Jose M Gatell; Brian G Gazzard; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Mauro Schechter; Robert T Schooley; Melanie A Thompson; Stefano Vella; Paul A Volberding Journal: JAMA Date: 2002-07-10 Impact factor: 56.272
Authors: Tanya L Kowalczyk Mullins; Gregory D Zimet; Susan L Rosenthal; Charlene Morrow; Lili Ding; Marcia Shew; J Dennis Fortenberry; David I Bernstein; Jessica A Kahn Journal: Arch Pediatr Adolesc Med Date: 2012-01
Authors: Jessica A Kahn; Jiahong Xu; Gregory D Zimet; Nancy Liu; René Gonin; Mary E Dillard; Kathleen Squires Journal: J Adolesc Health Date: 2011-11-04 Impact factor: 5.012
Authors: G E Gray; B Metch; G Churchyard; K Mlisana; M Nchabeleng; M Allen; Z Moodie; J Kublin; L-G Bekker Journal: Vaccine Date: 2013-01-29 Impact factor: 3.641
Authors: K M Andersson; E Vardas; L M Niccolai; R M Van Niekerk; M M Mogale; I M Holdsworth; M Bogoshi; J A McIntyre; G E Gray Journal: Int J STD AIDS Date: 2012-10 Impact factor: 1.359
Authors: Kyeen M Andersson; Douglas K Owens; Eftyhia Vardas; Glenda E Gray; James A McIntyre; A David Paltiel Journal: J Acquir Immune Defic Syndr Date: 2007-09-01 Impact factor: 3.731
Authors: Edith A M Tarimo; Anna Thorson; Thecla W Kohi; Muhammad Bakari; Eric Sandstrom; Fred Mhalu; Asli Kulane Journal: BMC Infect Dis Date: 2011-10-24 Impact factor: 3.090